| CCDS ID . | Protein . | Binding activity . | Activity Ratio . | |
|---|---|---|---|---|
| DR . | Control . | |||
| DR-high ligands with increased binding to diabetic ECs | ||||
| CCDS23347.1 | Scg3a | 1,731 | 0 | 1,732 |
| CCDS18810 | C1qba | 837 | 0 | 838 |
| CCDS15031 | Fn1a | 419 | 0 | 420 |
| CCDS35631 | Col4a3a | 409 | 2 | 137 |
| CCDS28285 | APPa | 206 | 1 | 104 |
| CCDS22638 | Cdh1a | 132 | 0 | 133 |
| DR-low ligands with decreased binding to diabetic ECs | ||||
| CCDS40011 | HRP-3a | 48 | 11,140 | 0.0044 |
| CCDS17457 | HDGFa | 0 | 83 | 0.0119 |
| Internal positive and negative controls | ||||
| VEGF-Phage | 408 | 2,420 | 0.1689 | |
| GFP-Phage | 10 | 10 | 1 | |
| Total identified sequences | 489,126 | 473,965 | ||
| Total identified ligands | 1,548 | 844 | ||
| Diabetes-related ligandsa | 353↑ | 105↓ | ||
| CCDS ID . | Protein . | Binding activity . | Activity Ratio . | |
|---|---|---|---|---|
| DR . | Control . | |||
| DR-high ligands with increased binding to diabetic ECs | ||||
| CCDS23347.1 | Scg3a | 1,731 | 0 | 1,732 |
| CCDS18810 | C1qba | 837 | 0 | 838 |
| CCDS15031 | Fn1a | 419 | 0 | 420 |
| CCDS35631 | Col4a3a | 409 | 2 | 137 |
| CCDS28285 | APPa | 206 | 1 | 104 |
| CCDS22638 | Cdh1a | 132 | 0 | 133 |
| DR-low ligands with decreased binding to diabetic ECs | ||||
| CCDS40011 | HRP-3a | 48 | 11,140 | 0.0044 |
| CCDS17457 | HDGFa | 0 | 83 | 0.0119 |
| Internal positive and negative controls | ||||
| VEGF-Phage | 408 | 2,420 | 0.1689 | |
| GFP-Phage | 10 | 10 | 1 | |
| Total identified sequences | 489,126 | 473,965 | ||
| Total identified ligands | 1,548 | 844 | ||
| Diabetes-related ligandsa | 353↑ | 105↓ | ||
P < 0.001; DR versus control; χ2 test. Activity ratio = (DR + 1)/(Control + 1).